Skip to main content
. Author manuscript; available in PMC: 2021 Mar 1.
Published in final edited form as: Ann Rheum Dis. 2019 Sep 20;79(3):332–338. doi: 10.1136/annrheumdis-2019-216109

Table 5.

Univariate analysis: IA treatment and follow-up tumour response (TR)

Medication exposure # of patients Worse TR* OR 95% CI P value
Systemic steroid 20 6 2.54 0.69 to 9.32 0.16
alone
csDMARD 19 2 0.34 0.07 to 1.74 0.20
bDMARD 11 2 0.82 0.15 to 4.43 0.82
Any DMARD 24 4 0.65 0.17 to 2.47 0.53
NSAIDS alone 7 1 0.61 0.07 to 5.58 0.66
*

Worse TR: worsened tumour response on follow-up assessment as compared with baseline tumour response (eg, a patient with stable disease at baseline had progression of disease at follow-up).

bDMARD, biological disease-modifying antirheumatic drugs; csDMARD, conventional synthetic disease modifying antirheumatic drugs; IA, inflammatory arthritis; NSAIDs, non-steroidal anti-inflammatory drugs.